April 22, 2020

MELFLUFEN SHOWS POSITIVE RESPONSE IN TRIPLE-REFRACTORY MULTIPLE MYELOMA TRIAL

Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides, announced.

These data will support a request for accelerated approval for melflufen to treat people with triple-refractory multiple myeloma in the U.S., the company said in a press release. The application is expected to be filed by midyear.

Melflufen belongs to a class of agents called peptidase-enhanced compounds, which work through a new mechanism of action. Once inside a cell, melflufen rapidly releases a toxic agent — an alkylating peptide — only when in contact with aminopeptidases, specific enzymes that are produced in excessive amounts by malignant cells, including those in multiple myeloma.

To read full article, click here